Donor stem cell transplant for high-risk multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new way of doing a stem cell transplant using cells from a donor to treat multiple myeloma that has come back or not responded to standard treatments. It also aims to prevent the cancer from coming back by using special cells that are not removed from the donor's stem cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have high-risk multiple myeloma that has come back or not responded well to previous treatments.
- You need to have a sibling or unrelated donor who is a close tissue match (7/8 or 8/8 matched).
- You must not have had a prior allogeneic (donor) stem cell transplant.
- You must have adequate organ function (kidney, liver, heart, and lungs) to undergo the transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
This trial looks at people with newly diagnosed multiple myeloma who have no detectable cancer cells after initial treatment. It aims to see if these patients can do well without a stem cell transplant or with a delayed one, reducing unnecessary side effects.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
This study looks at real-world outcomes in patients who have had a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to gather info on how well this approach works in everyday practice.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
Hear when a new Recurrent Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.